Understanding OUR Cytokine-Based Immunotherapy Candidates Our Commitment extends to advancing a robust portfolio of programs aimed at expanding the horizons of cytokine-based immunotherapy, especially for cancers where treatment choices remain limited. Use the links below to learn far more about our portfolio of cytokine-based immunotherapy candidates. Examine Our Pipeline https://financefeeds.com/norm-ai-secures-48-million-in-funding-to-expand-regulatory-ai-solutions/